Answers To Access, Adherence And Tolerance Of Protease Inhibitors

June 30, 1998

PROVIDENCE, R.I. - Protease inhibitors - the backbone ingredient of the potent triple therapy drug regimen - may not be performing as well in practice as they did in clinical trials, and some patients who could benefit from them may not be receiving them, according to three studies about access, adherence and tolerance of the potent drugs in 254 patients being treated at five urban sites in Boston and Rhode Island.

In one study, about 40 percent of 151 patients who tried one or more of the four available protease inhibitors eventually discontinued the drug. The most common reason patients gave was gastrointestinal and systemic side effects, followed by treatment failure, says lead author Valerie Stone, M.D., director of the Hope Center for HIV Care at Memorial Hospital in Pawtucket, R.I., and an assistant professor of medicine at Brown University.

"Patients can only benefit from protease inhibitors while they are taking the pills," Stone says. "If it turns out that regular patients in clinical practice aren't able to stick with the medications, they can't derive the benefits, such as increased survival and improved quality of life, that we've been led to expect." The take-home lesson is to optimize treatment regimens for individual patients and to closely manage side effects and toxicity, Stone says.

Despite the side effects and complex daily drug doses, most patients successfully adhere to their protease inhibitor therapy, except for those patients who have active substance abuse or alcohol problems, says another study Stone will present Wednesday, July 1.

Although they can stick to treatment, women, minorities and patients with less education are less likely to be offered potent drug cocktails containing protease inhibitors, according to another paper by Stone and colleagues to be given Thursday, July 2. "While combination regimens containing protease inhibitors can dramatically improve outcomes, not all patients who can benefit are receiving them even when clearly indicated," Stone says.

Media Contacts:
Valerie Stone M.D., (401) 729-2395, valerie_stone@mhri.org
-end-


Brown University

Related Side Effects Articles from Brightsurf:

Side effects often attributed to statins were the same for those taking a placebo
Study participants who reported side effects from cholesterol-lowering medications known as statins also reported the same side effects when they unknowingly took placebo pills.

Cancer treatment without side effects?
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine and Switzerland's Lausanne University Hospital may have found it.

Finding cortisone alternatives with fewer side effects
Many people use cortisone of a regular basis. It is used for treating rheumatism, asthma, multiple sclerosis, or even COVID-19.

Blood-thinner with no bleeding side-effects is here
In a study led by EPFL, scientists have developed a synthetic blood-thinner that, unlike all others, doesn't cause bleeding side-effects.

Predicting side effects
Scientists develop AI-based tool to predict adverse drug events. Such events are responsible for some 2 million U.S. hospitalizations per year.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

What if we could design powerful drugs without unwanted side effects?
The paper describes how to minimize or eliminate side effects in drugs that target G protein-coupled receptors.

Variation in how side effects are reported clouds drug safety
University of Colorado Cancer Center study finds significant variation in how drug side effects are reported, potentially making some drugs seem safer or less safe than they really are.

New drug can ease the side effects of medication against severe depression
Today, severe depressions require a high dose of antidepressants. However, the high dose may also cause serious side effects.

University of Cincinnati research looks at side effects for pediatric medications
Dr. Jeffrey Strawn, associate professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine, and Jeffrey Mills, associate professor in the Department of Economics at the UC Lindner College of Business, published a study in the Journal of the American Academy of Child & Adolescent Psychiatry looking specifically at side effects that impact children and adolescents being treated for anxiety disorders and obsessive-compulsive disorder (OCD).

Read More: Side Effects News and Side Effects Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.